Liquid Amber delivers strategic advising to DTx companies and investors with a focus on products with high scientific and regulatory complexity, including combined hardware/software packages, novel mechanisms of action and delivery methods, and combination drug/DTx products. In addition to advising on regulatory pathways and study designs (inc. sham comparators), Liquid Amber believes in the importance of helping clients build partnership with the FDA through regulatory communication (i.e. presubmissions). Driven by a mission to accelerate progress in the field of digital therapeutics as a whole, Liquid Amber facilitates information sharing through thought leadership and sponsorship of the DTx Conference Series poster sessions.